This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions
Generated Narrative: Evidence 236546
version: 65; Last updated: 2025-03-20 18:40:09+0000
Profile: ComparativeEvidence
RelatesTo
- type: part-of
- targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)
url: https://fevir.net/resources/Evidence/236546
identifier: FEvIR Object Identifier/https://fevir.net/FOI/236546, outcomeId/313878, picoId/85789, sectionId/73212
name: Nonfatal_myocardial_infarction_from_MAGICapp_313878
title: MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
Code | Value[x] |
Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | ComparativeEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
assertion:
GLP-1 receptor agonists probably reduce the risk of nonfatal myocardial infarction compared with standard care.
variableDefinition
description:
Adults with type 2 diabetes with moderate CV risk
variableRole: Population
observed: Adults with type 2 diabetes and established CVD (but no CKD)
variableDefinition
description:
GroupAssignment: GLP-1 RA vs. Standard care
variableRole: Exposure
comparatorCategory: Standard care
variableDefinition
description:
Nonfatal myocardial infarction
variableRole: Outcome
observed: Nonfatal myocardial infarction
synthesisType: SYSTEMATIC_REVIEW
studyDesign: randomized assignment
statistic
description:
Risk Difference -0.8% (CI95 -1.5% to -0.1%)
statisticType: Risk Difference
quantity: -0.008
SampleSizes
NumberOfStudies NumberOfParticipants 32 67956 AttributeEstimates
Type Range CI95 -0.015--0.001
statistic
description:
OR 0.92 (CI95 0.85 to 0.99)
statisticType: Odds Ratio
quantity: 0.92
SampleSizes
NumberOfStudies NumberOfParticipants 32 67956 AttributeEstimates
Type Range CI95 0.85-0.99
certainty
description:
Due to serious imprecision
type: Overall certainty
rating: Moderate certainty
Subcomponents
Type Rating Risk of Bias NOTSET Inconsistency NOTSET Indirectness NOTSET Imprecision NOTSET Publication Bias NOTSET